|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0025 - 0.0028|
|52 Week Range||0.0007 - 0.0150|
|Beta (5Y Monthly)||3.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
KATY, TX / ACCESSWIRE / September 14, 2021 / Neutra Corp. subsidiary VIVIS has signed a groundbreaking letter of intent (LOI) with a Houston clinical research company that, if it comes to a successful conclusion, would lead to testing hemp-based cannabinoids to treat COVD-19.
KATY, TX / ACCESSWIRE / August 26, 2021 / Neutra Corp. (OTC PINK:NTRR) subsidiary VIVIS is rolling out a new pricing structure designed to make its lab-tested, high-quality CBD products affordable to a wider range of consumers.
KATY, TX / ACCESSWIRE / August 16, 2021 / Neutra Corp. (OTC PINK:NTRR) continues to make substantial progress in securing distribution for its wholly-owned subsidiary VIVIS' CBD products.